CVAC CureVac Net earnings per share growth forecast for next year

CVAC (curevac.com) - company brandmark

The projected EPS growth rate for next year demonstrates the potential of mRNA pioneer CureVac N.V. (CVAC), whose optimized vaccines are effective in small doses. The value 0.00 represents the current level of this metric amid conservative eco-policies regarding bio-waste disposal. However, the German management must still confirm commercial success and defend its intellectual patents in court.

CVAC: CureVac Pharma Expected earnings per share growth for next year 07/04/2022 - 01/17/2026

curevac.com - analytical breakdowns and key metrics (CVAC)

- stock quotes and analyst forecast:
Stock Quotes CureVac Corp|CVAC - Analyst Consensus Forecast
- market capitalization data:
Market Value CureVac|CVAC - Company Buyout Price
- company book value details:
Book Value per Share CureVac|CVAC - Company Net Assets|Market Cap to Net Assets Ratio curevac.com|CVAC - Company Total Assets
- debt and liquidity data:
Debt to Equity CureVac N.V.|CVAC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital CureVac|CVAC - Company Cumulative Debt|Debt to Book Value CureVac|CVAC - Company Long-Term Debt|Company Short-Term Debts CureVac|Quick Ratio curevac.com
- earnings and valuation multiples information:
CVAC - Net Income|Future Profit CureVac N.V.|CVAC - Company Value to Net Income|Future Price to Earnings CureVac N.V.|CVAC - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio CureVac|CVAC - Operating income before deduction of amortization|Net earnings per share for the last 12 months CureVac|CVAC - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months curevac.com|CVAC - Expected net earnings per share growth this year|Earnings growth forecast for next year CureVac N.V.
Fundamental company analysis:CureVac Corp
Core merchandise of curevac.com

Professional capital evaluates CureVac N.V. (CVAC) through the lens of future cash flows, where the patent shield and alliance with GSK determine the scaling potential of the mRNA platform. Analyzing this chart of consensus EPS growth estimates for the coming year, the investor observes the expected profit trend, which allows for balancing the asset's current value against R&D cycle risks and determining the fundamental reliability of the investment.

Key competitors

Expected earnings per share growth for next year GILD|Earnings growth forecast for next year cidara.com|Net earnings per share growth forecast for next year Novavax, Inc. (NVAX)|Consensus forecast of earnings per share growth for next year valneva.com|Earnings growth forecast for next year VIR (Vir Biotechnology)|SIGA - Expected earnings per share growth for next year|EBS: Expected earnings per share growth for next year|AVIR - Earnings growth forecast for next year|invivyd.com (IVVD) - Net earnings per share growth forecast for next year|enanta.com - Expected earnings per share trend next year|INO (Inovio) - Earnings growth forecast for next year|Expected net earnings per share growth next year HilleVax Inc HLVX|Expected earnings per share growth for next year KLRS (Kalaris Therapeutics, Inc.)|Net earnings per share growth forecast for next year DYAI (dyadic.com)|Earnings growth forecast for next year NNVC (NanoViricides)|Earnings growth forecast for next year talphera.com TLPH|Cocrystal Pharma - Earnings growth forecast for next year|Traws Pharma, Inc. (TRAW) - Expected earnings per share growth for next year|DWTX (dwtx.com) - Expected earnings per share growth for next year|Qualigen Corp - Expected earnings per share trend next year|Net earnings per share growth forecast for next year AlloVir Inc|Projected earnings per share growth rate for next year VBIV (VBI Vaccines Inc)|Expected earnings per share growth for next year VIRI (Virios Therapeutics)|Consensus forecast of earnings per share growth for next year vaxart.com